SUNPHARMA.NS Profit & Loss
Sun Pharmaceutical Industries Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:42
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹43,885.68 Cr. | ₹48,496.85 Cr. | ₹52,578.44 Cr. | ₹58,462.04 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹634.52 Cr. | ₹1,354.19 Cr. | ₹1,965.04 Cr. | ₹1,971.72 Cr. | OtherIncome |
| Total Income | ₹44,520.20 Cr. | ₹49,851.04 Cr. | ₹54,543.48 Cr. | ₹60,433.76 Cr. | Income |
| Cost of Materials Consumed | ₹7,777.57 Cr. | ₹6,904.33 Cr. | ₹6,449.10 Cr. | ₹7,389.02 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹3,571.50 Cr. | ₹3,466.15 Cr. | ₹4,147.95 Cr. | ₹3,811.53 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-686.91 Cr. | ₹292.13 Cr. | ₹150.31 Cr. | ₹343.13 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹8,296.03 Cr. | ₹9,429.06 Cr. | ₹9,973.12 Cr. | ₹11,418.86 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹172.00 Cr. | ₹238.47 Cr. | ₹231.36 Cr. | ₹338.91 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹2,529.43 Cr. | ₹2,556.64 Cr. | ₹2,575.39 Cr. | ₹2,937.85 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹13,280.70 Cr. | ₹15,382.05 Cr. | ₹16,586.27 Cr. | ₹17,768.10 Cr. | OtherExpenses |
| Total Expenses | ₹34,940.32 Cr. | ₹38,268.83 Cr. | ₹40,113.50 Cr. | ₹44,007.40 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹9,579.88 Cr. | ₹11,582.21 Cr. | ₹14,429.98 Cr. | ₹16,426.36 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-171.45 Cr. | ₹-494.32 Cr. | ₹-677.85 Cr. | ₹-1,307.48 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹9,408.43 Cr. | ₹11,087.89 Cr. | ₹13,752.13 Cr. | ₹15,118.88 Cr. | ProfitBeforeTax |
| Tax Expense | ₹847.59 Cr. | ₹1,439.45 Cr. | ₹2,772.03 Cr. | ₹3,554.36 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹8,512.94 Cr. | ₹9,610.03 Cr. | ₹10,964.75 Cr. | ₹11,508.65 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹8,473.58 Cr. | ₹9,576.38 Cr. | ₹10,929.04 Cr. | ₹11,479.42 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹35.30 | ₹39.90 | ₹45.60 | ₹47.80 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹35.30 | ₹39.90 | ₹45.60 | ₹47.80 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from SUNPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).